PL401493A1 - Vanadium complexes with hydrazide-hydrazones, process for their preparation, pharmaceutical formulations and their use - Google Patents
Vanadium complexes with hydrazide-hydrazones, process for their preparation, pharmaceutical formulations and their useInfo
- Publication number
- PL401493A1 PL401493A1 PL401493A PL40149312A PL401493A1 PL 401493 A1 PL401493 A1 PL 401493A1 PL 401493 A PL401493 A PL 401493A PL 40149312 A PL40149312 A PL 40149312A PL 401493 A1 PL401493 A1 PL 401493A1
- Authority
- PL
- Poland
- Prior art keywords
- complexes
- vanadium
- group
- vanadium complexes
- hydrazones
- Prior art date
Links
- 150000003681 vanadium Chemical class 0.000 title abstract 3
- 238000000034 method Methods 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- -1 halogen anion Chemical class 0.000 abstract 3
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 abstract 2
- 239000003446 ligand Substances 0.000 abstract 2
- 230000007935 neutral effect Effects 0.000 abstract 2
- 239000002904 solvent Substances 0.000 abstract 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 abstract 1
- DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 abstract 1
- 150000001298 alcohols Chemical class 0.000 abstract 1
- 229910052783 alkali metal Inorganic materials 0.000 abstract 1
- 125000000129 anionic group Chemical group 0.000 abstract 1
- 229940111121 antirheumatic drug quinolines Drugs 0.000 abstract 1
- 125000004429 atom Chemical group 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 125000004430 oxygen atom Chemical group O* 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- SIOXPEMLGUPBBT-UHFFFAOYSA-N picolinic acid Chemical class OC(=O)C1=CC=CC=N1 SIOXPEMLGUPBBT-UHFFFAOYSA-N 0.000 abstract 1
- 150000003248 quinolines Chemical class 0.000 abstract 1
- 229910052720 vanadium Inorganic materials 0.000 abstract 1
- LEONUFNNVUYDNQ-UHFFFAOYSA-N vanadium atom Chemical group [V] LEONUFNNVUYDNQ-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/005—Compounds of elements of Group 5 of the Periodic Table without metal-carbon linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Przedmiotem wynalazku są kompleksy wanadu o wzorze ogólnym M[VX(ONO)y(L)n] mS, gdzie X oznacza atom tlenu lub jest nieobecny, L oznacza L1 lub L2, przy czym L1 oznacza anion fluorowca lub obojętną lub zdeprotonowaną cząsteczkę rozpuszczalnika wybranego z grupy zawierającej alkohole C1-C12 i/lub wodę, a L2 oznacza obojętny lub anionowy ligand NN, NO lub OO-donorowy wybrany z grupy zawierającej: polipirydyny, 1,10-fenantrolinę, pirony, chinoliny lub kwasy pirydynokarboksylowe, S oznacza obojętną cząsteczkę rozpuszczalnika wybranego z grupy zawierającej alkohole C1-C4, wodę lub kwas siarkowy, M może być nieobecny, a gdy jest obecny to oznacza jednododatni kation metalu alkalicznego, kation amonowy, kation alkiloamoniowy, a litery O i N oznaczają atom, przez który wiązany jest ligand do wanadu. Wynalazek obejmuje także sposób wytwarzania kompleksów wanadu, preparaty farmaceutyczne zawierające te kompleksy oraz ich zastosowanie.The present invention relates to vanadium complexes of the general formula M [VX (ONO) y (L) n] mS, where X is an oxygen atom or is absent, L is L1 or L2, wherein L1 is a halogen anion or an inert or deprotonated solvent molecule selected from the group containing C1-C12 alcohols and / or water, and L2 is a neutral or anionic NN, NO or OO-donor ligand selected from the group consisting of: polypyridines, 1,10-phenanthroline, pyrones, quinolines or pyridine carboxylic acids, S is a neutral molecule a solvent selected from the group consisting of C1-C4 alcohols, water or sulfuric acid, M may be absent, and when present it means a monopositive alkali metal cation, an ammonium cation, an alkylammonium cation, and the letters O and N are the atom through which the ligand is bound to vanadium. The invention also includes a method of making vanadium complexes, pharmaceutical preparations containing these complexes, and their use.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PL401493A PL231079B1 (en) | 2012-11-07 | 2012-11-07 | Vanadium complexes with hydrazide-hydrazones, process for their preparation, pharmaceutical formulations and their use |
| PCT/PL2013/000114 WO2014073992A1 (en) | 2012-11-07 | 2013-09-10 | Vanadium complexes with hydrazide-hydrazones, process for their preparation, pharmaceutical formulations and the use of thereof. |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PL401493A PL231079B1 (en) | 2012-11-07 | 2012-11-07 | Vanadium complexes with hydrazide-hydrazones, process for their preparation, pharmaceutical formulations and their use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| PL401493A1 true PL401493A1 (en) | 2014-05-12 |
| PL231079B1 PL231079B1 (en) | 2019-01-31 |
Family
ID=49486638
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL401493A PL231079B1 (en) | 2012-11-07 | 2012-11-07 | Vanadium complexes with hydrazide-hydrazones, process for their preparation, pharmaceutical formulations and their use |
Country Status (2)
| Country | Link |
|---|---|
| PL (1) | PL231079B1 (en) |
| WO (1) | WO2014073992A1 (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106432354B (en) * | 2016-09-30 | 2018-08-24 | 山西大学 | A kind of Schiff-base Palladium complex and its preparation method and application |
| CN106749393A (en) * | 2017-01-09 | 2017-05-31 | 山西大学 | Picoline hydrazonic acid derivative dioxygen vanadium（V）Complex and preparation method thereof |
| CN108623625A (en) * | 2018-07-11 | 2018-10-09 | 山东理工大学 | With active organic vanadium complex of para-insulin and preparation method thereof |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB328157A (en) | 1929-06-17 | 1930-04-24 | Ernest Edward Palmer | Improvements in and relating to manifolding books |
| CA1277599C (en) | 1986-10-16 | 1990-12-11 | Barry I. Posner | Vanadium - peroxide compositions as insulin mimickers |
| US5155031A (en) | 1990-06-07 | 1992-10-13 | Posner Barry I | Use of pervanadate as an inhibitor of phosphotyrosine phosphatase |
| FR2678622B1 (en) | 1991-07-03 | 1994-11-18 | Adir | NEW VANADIUM COMPLEXES, THEIR PREPARATION PROCESS AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. |
| IL99666A (en) | 1991-10-07 | 1996-09-12 | Yeda Res & Dev | Vanadyl complexes of hydroxamate chelators and pharmaceutical compositions comprising them |
| US5565491A (en) | 1994-01-31 | 1996-10-15 | Bristol-Myers Squibb Company | Use of phosphotyrosine phospatase inhibitors for controlling cellular proliferation |
| NL1006681C2 (en) | 1997-07-29 | 1999-02-08 | Gho St Holding Bv | Application of physiologically acceptable vanadium compounds, salts and complexes. |
| IL121748A0 (en) | 1997-09-11 | 1998-02-22 | Yeda Res & Dev | Vanadium complexes of hydroxamates and pharmaceutical compositions comprising them |
| US6432941B1 (en) | 1998-01-20 | 2002-08-13 | Parker Hughes Institute | Vanadium compounds for treating cancer |
| GB0328157D0 (en) | 2003-12-04 | 2004-01-07 | Imp College Innovations Ltd | Compounds |
| US8008035B2 (en) | 2007-01-25 | 2011-08-30 | Roche Diagnostics Operations, Inc. | Enhancement of vanadium-containing phosphatase inhibitors |
| US8242092B2 (en) | 2008-02-05 | 2012-08-14 | Brent Townshend | Protein tyrosine phosphatase inhibitors |
-
2012
- 2012-11-07 PL PL401493A patent/PL231079B1/en unknown
-
2013
- 2013-09-10 WO PCT/PL2013/000114 patent/WO2014073992A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| WO2014073992A1 (en) | 2014-05-15 |
| PL231079B1 (en) | 2019-01-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX388603B (en) | COMPOSITION OF THE DRYER AND ITS USE. | |
| Chalkidou et al. | Copper (II) complexes with antimicrobial drug flumequine: Structure and biological evaluation | |
| FR22C1012I1 (en) | HERBICIDE COMPOSITIONS CONTAINING 4-AMINO-3-CHLORO-5-FLUORO-6-(4-CHLORO-2-FLUORO-3-METHOXYPHENYL)PYRIDINE-2-CARBOXYLIC ACID | |
| CN102304063B (en) | Schiff base ligand and metal complex thereof and use of Schiff base ligand and metal complex thereof | |
| Rangel et al. | Spectroscopic and potentiometric characterization of oxovanadium (IV) complexes formed by 3-hydroxy-4-pyridinones. Rationalization of the influence of basicity and electronic structure of the ligand on the properties of VIVO species in aqueous solution | |
| EP2877020A4 (en) | HERBICIDE COMPOSITIONS CONTAINING 4-AMINO-3-CHLORO-5-FLUORO-6- (4-CHLORO -2-FLUORO-3-METHOXYPHENYL) PYRIDINE -2-CARBOXYLIC ACID | |
| EP2877006A4 (en) | HERBICIDE COMPOSITIONS CONTAINING 4-AMINO-3-CHLORO-5-FLUORO-6- (4-CHLORO -2-FLUORO-3-METHOXYPHENYL) PYRIDINE -2-CARBOXYLIC ACID | |
| SA518392321B1 (en) | Coordination Complexes Containing Monosulfonated Catecholate Ligands and Methods for Producing the same | |
| EP2877022A4 (en) | HERBICIDAL COMPOSITIONS COMPRISING 4-AMINO-3-CHLORO-5-FLUORO-6- (4-CHLORO-2-FLUORO-3-METHOXYPHENYL) PYRIDINE-2-CARBOXYLIC ACID | |
| MY193378A (en) | Compositions comprising peg and ascorbate | |
| EA201201268A1 (en) | SYNTHESIS OF ALPHA-TOCOFEROLHKHINON DERIVATIVES AND METHODS OF THEIR APPLICATION | |
| MX2020013371A (en) | Dicarboxylic acid bisamide derivatives, use thereof, pharmaceutical composition based thereon and methods for producing dicarboxylic acid bisamide derivatives. | |
| PL408565A1 (en) | MOF metal-organic frameworks with [M2(dcx)2L2] formula, containing dicarboxylates (dcx) and hydrazones (L), method for obtaining them and applications | |
| GB2500128A (en) | Colonoscopy-preparation | |
| MX2012008885A (en) | Extraction process. | |
| IN2014MN01495A (en) | ||
| PH12015500122A1 (en) | Herbicidal compositions comprising 4-amino-3-chloro-5-fluoro-6-(4-chloro-2-fluoro-3-methoxyphenyl) pyridine-2-carboxylic acid or a derivative thereof and a sulfonylaminocarbonyltriazolinone | |
| WO2016015066A8 (en) | Method for producing a liquid pharmaceutical preparation | |
| Puente et al. | Direct electrochemical synthesis of metal complexes | |
| WO2017191604A3 (en) | In-kit preparation of gallium-68 labelled radiopharmaceuticals | |
| MX2019010886A (en) | Mesostigmata mite control agent. | |
| Caporali et al. | The first water-soluble tetraphosphorus ruthenium complex. Synthesis, characterization and kinetic study of its hydrolysis | |
| MX2010008663A (en) | Process for preparing substituted biphenylanilides. | |
| CN103992355A (en) | Cobalt quaternary complex [Co(4,4'-bpt)2(O-BDC)(H2O)3]NO3·H2O and its preparation method | |
| KR101548806B1 (en) | Novel Compounds, Agent Selecting Chromium Ion Or Aluminum Ion Using The Same, Detecting Method And Detecting Device Thereof |